Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications
Enhancing Gemcitabine Uptake by Promoting Dimerization of the ENT1 Transporter Improves Sarcoma Patient Response Rate.
Journal: The Journal of clinical investigation
Published: September 03, 2026
Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 27, 2026
Pleomorphic Liposarcoma: Comprehensive Genomic Analysis of 39 Cases With Comparison to Other Genomically Complex Sarcomas.
Journal: Genes, chromosomes & cancer
Published: June 20, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.
Journal: Journal for immunotherapy of cancer
Published: April 15, 2026
A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.
Journal: Future oncology (London, England)
Published: December 22, 2025
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.
Journal: ESMO open
Published: October 29, 2025
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 10, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: July 16, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.
Journal: Cancer research communications
Published: June 25, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2025
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma.
Journal: ESMO open
Published: May 21, 2025
Last Updated: 09/26/2026